HIA
ACAD icon

HFM Investment Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

HFM Investment Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$156 Hold
7
– – ﹤0.01% 1050
2025
Q4 		$187 Sell
7
-2
-22% -$48 ﹤0.01% 1040
2025
Q3 		$192 Buy
9
+2
+29% +$47 ﹤0.01% 1005
2025
Q2 		$151 Buy
+7
New +$130 ﹤0.01% 1069

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

HFM Investment Advisors's ACAD Position: Q1 2026 in Review

HFM Investment Advisors held its Acadia Pharmaceuticals (ACAD) position steady in Q1 2026 at 7 shares worth $156. The position accounts for ﹤0.01% of the portfolio, ranked #1050.

HFM Investment Advisors first reported a position in ACAD in Q2 2025 and has held it in 4 quarters since. The position peaked at $192 in Q3 2025. 340 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

  • HFM Investment Advisors held 7 shares of Acadia Pharmaceuticals worth $156 as of Q1 2026.
  • HFM Investment Advisors left its Acadia Pharmaceuticals share count unchanged in Q1 2026.
  • Acadia Pharmaceuticals made up ﹤0.01% of HFM Investment Advisors's portfolio in Q1 2026, its #1050 holding.
  • HFM Investment Advisors first reported a position in Acadia Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • HFM Investment Advisors's Acadia Pharmaceuticals position peaked at $192 in Q3 2025.
  • 340 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on HFM Investment Advisors's 13F filing for Q1 2026, filed 1 May 2026.